A Phase I Dose Escalation Randomized, Double-blind, Placebo-controlled Safety and Immunogenicity Trial of the Reactivation of Pertussis Toxin Immunity With the Viaskin Epicutaneous Delivery System in Healthy Adults
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2017
At a glance
- Drugs Pertussis vaccine (Primary)
- Indications Pertussis
- Focus Adverse reactions; Pharmacodynamics; Proof of concept
- Sponsors DBV Technologies
- 01 Aug 2017 Last checked against ClinicalTrials.gov record.
- 27 Jul 2017 Planned End Date changed from 1 Apr 2017 to 1 Jan 2018.
- 27 Jul 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Jan 2018.